French vascular physicians' practices in indicating antiplatelet and anticoagulation therapy in venous

Antoine Fayol1, Damien Lanéelle2, Clément Hoffmann3

  • 11 Service de Médecine Interne, Hôpital Louis Mourier (Colombes), Assistance Publique - Hôpitaux de Paris (APHP), Université Paris 7, Paris, France.

Insights

French vascular physicians acknowledge increased bleeding risk when combining antiplatelet agents (APA) and anticoagulants for venous thromboembolism (VTE). Management strategies varied significantly among physicians, highlighting the need for comparative trials.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Clinical Pharmacy

Background:

  • Widespread antiplatelet therapy (APA) use presents challenges in managing patients requiring anticoagulation for venous thromboembolism (VTE).
  • Combining APA and anticoagulants increases bleeding risk by 1.5-2.5 fold.
  • Current management strategies for this dual therapy in VTE patients are not standardized.

Purpose of the Study:

  • To evaluate the management practices of French vascular physicians regarding the combined use of APA and anticoagulants in VTE patients.
  • To assess physician approaches at both the initiation of treatment and at the 6-month follow-up point.

Main Methods:

  • A survey was conducted among French vascular physicians between September and December 2017.
  • The survey utilized fictional scenarios and isolated questions presented via an online questionnaire.
  • 179 valid responses were collected from 1812 physicians, yielding a 9.9% response rate.

Main Results:

  • 97.2% of physicians recognized the elevated bleeding risk associated with combined APA and anticoagulant therapy.
  • 63% of respondents discontinued APA upon initiating anticoagulation, while 36% did not.
  • Four distinct management strategies were identified, with variations in anticoagulant dosage and APA continuation at 6 months.

Conclusions:

  • French vascular physicians employ diverse treatment strategies based on perceived risk-benefit ratios.
  • Significant heterogeneity exists in clinical practice for managing VTE patients on dual antiplatelet and anticoagulant therapy.
  • Further randomized controlled trials are necessary to establish evidence-based recommendations for optimal management.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...